Antiepileptic — Sodium Channel Slow Inactivation Enhancer
Pregnancy: Avoid — limited data; use effective contraception
Lacosamide
Brand names: Vimpat
Adult dose
Dose: 50 mg twice daily initially; target 100–200 mg twice daily
Route: Oral / IV
Frequency: Twice daily
Max: 400 mg/day
Novel mechanism: selectively enhances slow inactivation of voltage-gated Na+ channels — distinct from carbamazepine/phenytoin (fast inactivation). Licensed as monotherapy or adjunct for focal seizures. IV formulation available for acute use when oral not possible.
Paediatric dose
Dose: 1 mg/day/kg
Route: Oral
Frequency: Twice daily
Max: 12 mg/kg/day (max 400 mg/day)
Children ≥4 years: 1–2 mg/kg BD increasing to 4–6 mg/kg BD (max 200 mg BD). Weight-based dosing.
Dose adjustments
Renal
Max 250 mg/day if eGFR <30 mL/min.
Hepatic
Max 250 mg/day in hepatic impairment.
Paediatric weight-based calculator
Children ≥4 years: 1–2 mg/kg BD increasing to 4–6 mg/kg BD (max 200 mg BD). Weight-based dosing.
Clinical pearls
- ECG before initiating and after dose increases — PR prolongation risk; avoid in 2nd/3rd degree AV block
- IV-to-oral switch: 1:1 equivalence — ideal for acute hospital setting when oral route unavailable
- No significant drug interactions via CYP450 induction — minimal effect on contraceptives or warfarin; advantage over enzyme-inducing AEDs
Contraindications
- 2nd or 3rd degree AV block
- Hypersensitivity to lacosamide
Side effects
- Dizziness and diplopia
- Nausea
- Headache
- PR prolongation (ECG monitoring required)
- Ataxia
- Depression
Interactions
- Drugs prolonging PR interval (additive — beta-blockers, calcium channel blockers, digoxin)
- CYP2C19 inhibitors (omeprazole — modest increase in lacosamide levels)
Monitoring
- ECG (PR interval)
- Seizure diary
- LFTs and renal function at baseline
Reference: BNFc; BNF 90; NICE NG217; EMA Vimpat SPC; BNFc. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS